Clostridioides difficile (C. difficile or C. diff) is a type of bacteria that causes a range of gastrointestinal symptoms, from mild diarrhoea to life-threatening colitis. It affects the colon, which ...

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge ...

Clostridioides difficile is a notoriously nasty intestinal bug, with few effective treatments and no approved vaccines. But the same technology that enabled the first COVID-19 vaccines has shown early ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary ...

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff). Scientists have made a breakthrough in the hunt for a new vaccine for ...

Mice fed a high-fat, high-protein diet were more likely to develop and die from antibiotic-driven Clostridioides difficile infections than mice fed a standard diet. In the same study, a ...

This year in review of 2025 milestones in Clostridioides difficile infection features coverage of research on infection patterns presented at the American Society for Microbiology Microbe 2025 meeting ...

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...